| Literature DB >> 25806957 |
Jin-Ha Yoon1, Jang-Young Kim2, Jong-Ku Park3, Sang-Baek Ko3.
Abstract
BACKGROUND: This study aimed to assess the association between oxidative damage markers and carotid artery intima-media thickness (CIMT) after controlling for conventional risk factors of atherosclerosis in multiple logistic regression models. METHODS ANDEntities:
Mesh:
Substances:
Year: 2015 PMID: 25806957 PMCID: PMC4373810 DOI: 10.1371/journal.pone.0119731
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and metabolic characteristics of the case and control groups.
| Cases (n = 51)CIMT ≥0.9 mm | Controls (n = 51)CIMT < 0.9 mm |
| |||
|---|---|---|---|---|---|
|
| |||||
| Age, n (%) | 1.000 | ||||
| 40~50 | 2 | (3.92) | 2 | (3.92) | |
| 51~60 | 14 | (27.45) | 14 | (27.45) | |
| 61~70 | 29 | (56.86) | 29 | (56.86) | |
| 71~80 | 6 | (11.76) | 6 | (11.76) | |
| Pharmacologic treatments, n (%) | |||||
| Hypertension | 18 | (35.29) | 20 | (39.22) | 0.6821 |
| Diabetes | 6 | (11.76) | 5 | (9.08) | 0.7496 |
| Dyslipidemia | 6 | (11.76) | 9 | (17.65) | 0.4016 |
| % of never smoker, n (%) | 19 | (37.25) | 24 | (47.06) | 0.4239 |
| % of alcohol drinker, n (%) | 34 | (66.67) | 35 | (68.63) | 0.8324 |
|
| |||||
| Isoprostane / creatinine ratio | 0.50 | (0.27–0.80) | 0.21 | (0.15–0.47) | <.0001 |
| 8-OHdG / creatinine ratio | 1.26 | (0.69–1.83) | 0.74 | (0.45–1.14) | 0.0021 |
| MDA / creatinine ratio | 0.20 | (0.13–0.28) | 0.11 | (0.08–0.16) | 0.0005 |
| Triglyceride (mg/dL) | 133.00 | (97–177) | 128.00 | (84–159) | 0.2955 |
| Body mass index (kg/m2) | 23.98 | ±2.73 | 24.20 | ±2.93 | 0.6935 |
| Waist circumference (cm) | 85.25 | ±5.78 | 86.11 | ±7.71 | 0.5289 |
| Fasting plasma glucose (mg/dL) | 104.92 | ±24.73 | 98.75 | ±14.23 | 0.1290 |
| Systolic blood pressure (mmHg) | 127.48 | ±14.55 | 126.88 | ±14.92 | 0.8390 |
| Diastolic blood pressure (mmHg) | 76.94 | ±11.72 | 80.59 | ±9.55 | 0.0893 |
| LDL (mg/dL) | 117.58 | ±25.94 | 106.02 | ±31.07 | 0.0453 |
| HDL (mg/dL) | 50.02 | ±9.89 | 51.65 | ±12.44 | 0.4692 |
| MetS proportion (n, %) | 17 | (33.30) | 18 | (35.29) | 0.8348 |
| eGFR (mL/min/1.73 m2) | 79.34 | x12.55 | 76.97 | ±11.28 | 0.3163 |
Abbreviations: CIMT, carotid intima media thickness; BMI, body mass index; Isoprostane, 8-iso-prostaglandin F2α; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; MDA, malondialdehyde; MetS, metabolic syndrome; LDL, low density lipoprotein; HDL, high density lipoprotein; eGFR, estimated glomerular filtration rate.
Independent relationship among oxidative damage markers to carotid intima media thickness.
| Model A | Model B | Model C | Model D | ||
|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | ||
|
| 1st tertile (<0.21) | 1.00 - | 1.00 - | 1.00 - | |
| 2nd tertile (<0.51) | 4.72 (1.37–16.20) | 3.37 (0.98–11.63) | 3.93 (1.08–14.25) | ||
| 3rd tertile (≥0.51) | 16.61 (3.44–80.15) | 9.84 (2.12–45.70) | 11.73 (2.30–59.74) | ||
|
| 1st tertile (<0.10) | 1.00 - | 1.00 - | 1.00 - | |
| 2nd tertile (<0.20) | 2.83 (0.80–10.06) | 3.93 (1.15–13.45) | 2.47 (0.66–9.20) | ||
| 3rd tertile (≥0.20) | 4.74 (1.33–16.94) | 3.59 (0.94–13.64) | 2.38 (0.55–10.23) | ||
|
| 1st tertile (<0.66) | 1.00 - | 1.00 - | 1.00 - | |
| 2nd tertile (<1.26) | 0.58 (0.15–2.30) | 0.81 (0.21–3.10) | 0.77 (0.18–3.34) | ||
| 3rd tertile (≥1.26) | 4.25 (1.05–17.16) | 3.16 (0.83–12.10) | 4.04 (0.94–17.50) | ||
All models were adjusted for age, body mass index, smoking history, regular alcohol consumptions, systolic blood pressure, fasting plasma glucose, low density lipoprotein, glomerular filtration rate and pharmacological treatment of hypertension, diabetes and dyslipidemia
Abbreviations: Isoprostane, 8-iso-prostaglandin F2α; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; MDA, malondialdehyde; OR (95% CI), odds ratio (95% confidence interval), OR (95% CI): odds ratio (95% confidence interval).
Relationship between oxidative damage marker and carotid artery intima media thickness (mm).
| Model I | Model II | |||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
|
| OR (95% CI) | 1st tertile (<0.21) | 1.00 - | 1.00 - |
| 2nd tertile (<0.51) | 3.80 (1.36–10.59) | 4.221 (1.31–13.53) | ||
| 3rd tertile (≥0.51) | 7.30 (2.50–21.29) | 14.21 (3.34–60.56) | ||
| P for trend | <0.001 | <0.001 | ||
|
| OR (95% CI) | 1st tertile (<0.10) | 1.00 - | 1.00 - |
| 2nd tertile (<0.20) | 3.08 (1.13–8.42) | 4.22 (1.27–13.99) | ||
| 3rd tertile (≥0.20) | 6.39 (2.24–18.25) | 6.46 (1.91–21.83) | ||
| P for trend | 0.001 | 0.002 | ||
|
| OR (95% CI) | 1st tertile (<0.66) | 1.00 - | 1.00 - |
| 2nd tertile (<1.26) | 1.34 (0.48–3.78) | 0.77 (0.22–2.64) | ||
| 3rd tertile (≥1.26) | 5.43 (1.86–15.84) | 4.45(1.27–15.56) | ||
| P for trend | 0.002 | 0.020 | ||
ORs were calculated at level of carotid intima media thickness > 10 mm.
P for trend were calculated by conditional logistic regression models.
Abbreviations: Isoprostane, 8-iso-prostaglandin F2α; 8-OHdG, 8-hydroxy-2'-deoxyguanosine; MDA, malondialdehyde; OR (95% CI), odds ratio (95% confidence interval), OR (95% CI): odds ratio (95% confidence interval).
Model I: not adjusted
Model II: adjusted for age, smoking history, regular alcohol consumptions, systolic blood pressure, fasting blood glucose, low density lipoprotein, glomerular filtration rate and pharmacological treatment of hypertension, diabetes and dyslipidemia.